And I think it is very important because this means that we can probably expand our clinical outcome battery, say, and use this, uh, reported by patients.

Yeah.

I, I strongly agree, Carmen.

Um, I think that multidimensional, uh, data, uh, and also moving a- away from some of the traditional definitions that we've used for MS disease stages are gonna be key to, uh, to really personalizing care.

Um, if I may, um, I think we need to remember that more data do not rescue a poorly defined clinical question.

And so what I really mean by this is The randomised control trial i-is the gold standard for proving cause and effect a-and the reason for that, uh, or the lessons from it are ones that we can take into observational work.

Uh, and, uh, of course there's been a big emphasis on this on target trial emulation recently.

How do you see these predictive modeling programs essentially being implemented into clinical practice and starting to influence treatment decisions as a starting point? And then what do you see as the, the things that still need to happen for it to get to that point?